OUTCOME OF CHEMORADIATION THERAPY FOR MUSCLE INVASIVE BLADDER CANCER

Dr. Maria Sophia J, Dr. Hasib A. G

Abstract


Aim: To study treatment outcome in carcinoma urinary bladder patients who underwent chemoradiation.
Methods: A single institutional study of patients of muscle invasive bladder carcinoma treated with transurethral resection of bladder tumour
(TURBT) followed by chemoradiation from January 2014-january 2019 where retrospectively evaluated for response after treatment.
Results: A total of 24 patients were treated from 2014-2019. Age group of 46-84years, mean age 65year. 20 patients were males and 4 female
patients. All 24 patients underwent TURBT and radiation therapy. Radical radiation was changed to palliative radiation in 2 patients (due to
deteriorating general condition and progressive disease). Rest of 21 patients received concurrent chemoradiation with average dose of 60-66 Gy in
33 fractions, 2Gy per dose fraction. Of this 24 patients, 3 patients expired during the course of treatment, (1patient had seizure disorder and
developed aspiration pneumonia,1 due to cardiac arrest and renal failure due volume over load, other patient had sudden cardiac arrest). Complete
response was seen in 9 patients, 3 patients had residual disease, 5 patients had progressive disease and 4patients were lost to follow up. Grade 1-
3 toxicities were seen during treatment and no grade 4 acute or late toxicity was encountered.
Conclusion: Most of the patients referred to radiation were elderly patients with multiple comorbidities with poor performance status. Our results
demonstrate that radiation dose above 60Gy is associated with improved bladder preserved overall survival rates. Overall, concurrent
chemoradiation in muscle invasive bladder cancer has demonstrated reasonable efficacy.


Full Text:

PDF

References


Petrovich Z, Jozsef G, Brady LW. Radiotherapy for carcinoma of the bladder: a review. Am J Clin Oncol. 2001;24:1–9.

Rödel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. Journal of clinical oncology. 2006 Dec 10;24(35):5536-44.

Mameghan H, Fisher R, Mameghan J, Brook S. Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. International Journal of Radiation Oncology• Biology• Physics. 1995 Jan 15;31(2):247-54.

Gospodarowicz MK, Hawkins NV, Rawlings GA, Connolly JG, Jewett MA, Thomas GM, Herman JG, Garrett PG, Chua T, Duncan W, Buckspan M. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. The Journal of urology. 1989 Dec;142(6):1448-53.

Pollack A, Zagars GZ. Radiotherapy for stage T3b transitional cell carcinoma of the bladder. InSeminars in urologic oncology 1996 May (Vol. 14, No. 2, pp. 86-95).

De Neve W, Lybeert ML, Goor C, Crommelin MA, Ribot JG. Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Radiotherapy and Oncology. 1995 Sep 1;36(3):183-8.

Duncan W, Quilty PM. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiotherapy and Oncology. 1986 Jan 1;7(4):299-310.

Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. Journal of Clinical Oncology. 2014 Dec 1;32(34):3801.

Munro NP, Sundaram SK, Weston PM, Fairley L, Harrison SC, Forman D, Chahal R. A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK. International Journal of Radiation Oncology* Biology* Physics. 2010 May 1;77(1):119-24.

Kotwal S, Choudhury A, Johnston C, Paul AB, Whelan P, Kiltie AE. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. International Journal of Radiation Oncology* Biology* Physics. 2008 Feb 1;70(2):456-63.

Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, Studer UE. Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy. Journal of clinical oncology. 2003 Feb 15;21(4):690-6.

Dalbagni G, Genega E, Hashibe MI, Zhang ZF, Russo P, Herr H, Reuter V. Cystectomy for bladder cancer: a contemporary series. The Journal of urology. 2001 Apr;165(4):1111-6.

Yu JI, Park W, Oh DR, Huh SJ, Choi HY, Lee HM, Jeon SS, Yim HY, Kim WS, Lim DH, Ahn YC. Bladder preserving treatment in patients with muscle invasive bladder cancer. The Journal of the Korean Society for Therapeutic Radiology and Oncology. 2007 Jun 1;25(2):70-8.


Refbacks

  • There are currently no refbacks.